» Articles » PMID: 11854515

Synergistic Effects of L- and P-selectin in Facilitating Tumor Metastasis Can Involve Non-mucin Ligands and Implicate Leukocytes As Enhancers of Metastasis

Overview
Specialty Science
Date 2002 Feb 21
PMID 11854515
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

P-selectin facilitates human carcinoma metastasis in immunodeficient mice by mediating early interactions of platelets with bloodborne tumor cells via their cell surface mucins, and this process can be blocked by heparin [Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M. & Varki, A. (2001) Proc. Natl. Acad. Sci. USA 98, 3352-3357]. Here we show similar findings with a murine adenocarcinoma in syngeneic immunocompetent mice but involving a different P-selectin ligand, possibly a sulfated glycolipid. Thus, metastatic spread can be facilitated by tumor cell selectin ligands other than mucins. Surprisingly, L-selectin expressed on endogenous leukocytes also facilitates metastasis in both the syngeneic and xenogeneic (T and B lymphocyte deficient) systems. PL-selectin double deficient mice show that the two selectins work synergistically. Although heparin can block both P- and L-selectin in vitro, the in vivo effect of a single heparin dose given before tumor cells seems to be completely accounted for by blockade of P-selectin function. Thus, L-selectin on neutrophils, monocytes, and/or NK cells has a role in facilitating metastasis, acting beyond the early time points wherein P-selectin mediates interactions of platelet with tumor cells.

Citing Articles

Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.

Vogt K, Silberman P, Lin Q, Han J, Laflin A, Gellineau H Sci Adv. 2025; 11(4):eads3403.

PMID: 39841845 PMC: 11753401. DOI: 10.1126/sciadv.ads3403.


Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis.

Asmael Al-Azzawi H, Hamza S, Paolini R, Arshad F, Patini R, OReilly L Front Oral Health. 2024; 5:1495942.

PMID: 39568788 PMC: 11576436. DOI: 10.3389/froh.2024.1495942.


Von Willebrand factor and hematogenous cancer metastasis under flow.

Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.

PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.


The impact of platelets on the metastatic potential of tumour cells.

Raskov H, Orhan A, Agerbaek M, Gogenur I Heliyon. 2024; 10(14):e34361.

PMID: 39114075 PMC: 11305202. DOI: 10.1016/j.heliyon.2024.e34361.


Immune Cell Migration to Cancer.

Ryan A, Kim M, Lim K Cells. 2024; 13(10.

PMID: 38786066 PMC: 11120175. DOI: 10.3390/cells13100844.


References
1.
Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y . Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993; 53(15):3632-7. View

2.
Lowe J . Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Kidney Int. 1997; 51(5):1418-26. DOI: 10.1038/ki.1997.194. View

3.
Tang M, Steeber D, Zhang X, Tedder T . Intrinsic differences in L-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways. J Immunol. 1998; 160(10):5113-21. View

4.
Hakomori S . Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996; 56(23):5309-18. View

5.
Gasic G . Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984; 3(2):99-114. DOI: 10.1007/BF00047657. View